Aporphines and Alzheimer’s Disease: Towards a Medical Approach Facing the Future

Author(s): Seyed Mohammad Nabavi , Eugenio Uriarte , Luca Rastrelli , Eduardo Sobarzo-Sánchez* .

Journal Name: Current Medicinal Chemistry

Volume 26 , Issue 18 , 2019

  Journal Home
Translate in Chinese

Abstract:

Alzheimer's disease (AD) is a neurodegenerative disease that reduces progressively the part cognitive inside the Central Nervous System (CNS) and that affects the memories and emotions of the patients who endure this disease. Many drugs have been assessed in patients with different evolutionary grades of the disease, having diverse results, depending on the used compound. Some of them afford dependence and many others with side effects that affect the emotional part and the economic cost of the treatment. The natural products have diversified their therapeutic uses, and have been used in the treatment of AD in accordance with its easy medical administration and bioavailability. In this review, the use of aporphines in nature for treating Alzheimer's disease, alkaloids isolated from natural and/or synthetic sources have been used principally as cholinesterase inhibitors (acetyl- and butyrylcholinesterase) as galantamine, for instance, though its use has been questioned for being slightly effective or marginal. The use of aporphines give the possibility of generating new treatments with nitrogenous chemical structures of diverse complexity and that are focused in this review comparatively and with real therapeutic scopes.

Keywords: Aporphines, apomorphine, oxoaporphines, Alzheimer's disease, dopamine, neurodegenerative disease.

[1]
Alzheimer’s Association 2014 Alzheimer’s disease facts and figures. Alzheimers Dement., 2014, 10(2), e47-e92.
[http://dx.doi.org/10.1016/j.jalz.2014.02.001] [PMID: 24818261]
[2]
Tanzi, R.E.; Bertram, L. Twenty years of the Alzheimer’s disease amyloid hypothesis: A genetic perspective. Cell, 2005, 120(4), 545-555.
[http://dx.doi.org/10.1016/j.cell.2005.02.008] [PMID: 15734686]
[3]
World Health Organization and Alzheimer’s Disease InternationalDementia: a public health priority; , 2012, pp. 1- 102.ISBN: 978 92 4 1564458.
[4]
Götz, J.; Ittner, L.M. Animal models of Alzheimer’s disease and frontotemporal dementia. Nat. Rev. Neurosci., 2008, 9(7), 532-544.
[http://dx.doi.org/10.1038/nrn2420] [PMID: 18568014]
[5]
Pohanka, M. Cholinesterases, a target of pharmacology and toxicology. Biomed. Pap., 2011, 155, 219-229.
[http://dx.doi.org/10.5507/bp.2011.036] [PMID: 22286807]
[6]
Pohanka, M.; Adam, V.; Kizek, R. An acetylcholinesterase-based chronoamperometric biosensor for fast and reliable assay of nerve agents. Sensors (Basel), 2013, 13(9), 11498-11506.
[http://dx.doi.org/10.3390/s130911498] [PMID: 23999806]
[7]
Scarpini, E.; Scheltens, P.; Feldman, H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol., 2003, 2(9), 539-547.
[http://dx.doi.org/10.1016/S1474-4422(03)00502-7] [PMID: 12941576]
[8]
Muñoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr. Med. Chem., 2008, 15(24), 2433-2455.
[http://dx.doi.org/10.2174/092986708785909067] [PMID: 18855672]
[9]
Terry, A.V. Jr. Buccafusco, J.J. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther., 2003, 306(3), 821-827.
[http://dx.doi.org/10.1124/jpet.102.041616] [PMID: 12805474]
[10]
Chen, Y.; Xu, X.; Fu, T.; Li, W.; Liu, Z.; Sun, H. Discovery of new scaffolds from approved drugs as acetylcholinesterase inhibitors. RSC Advances, 2015, 5, 90288-90294.
[http://dx.doi.org/10.1039/C5RA19551A]
[11]
Pohanka, M. Copper, aluminum, iron and calcium inhibit human acetylcholinesterase in vitro. Environ. Toxicol. Pharmacol., 2014, 37(1), 455-459.
[http://dx.doi.org/10.1016/j.etap.2014.01.001] [PMID: 24473150]
[12]
Luo, Z.; Sheng, J.; Sun, Y.; Lu, C.; Yan, J.; Liu, A.; Luo, H.B.; Huang, L.; Li, X. Synthesis and evaluation of multi-target-directed ligands against Alzheimer’s disease based on the fusion of donepezil and ebselen. J. Med. Chem., 2013, 56(22), 9089-9099.
[http://dx.doi.org/10.1021/jm401047q] [PMID: 24160297]
[13]
Yang, Z.; Song, Z.; Xue, W.; Sheng, J.; Shu, Z.; Shi, Y.; Liang, J.; Yao, X. Synthesis and structure-activity relationship of nuciferine derivatives as potential acetylcholinesterase inhibitors. Med. Chem. Res., 2014, 23, 3178-3186.
[http://dx.doi.org/10.1007/s00044-013-0905-9]
[14]
Ribarič, S. The pharmacological properties and therapeutic use of apomorphine. Molecules, 2012, 17(5), 5289-5309.
[http://dx.doi.org/10.3390/molecules17055289] [PMID: 22565480]
[15]
Cometa, M.F.; Fortuna, S.; Palazzino, G.; Volpe, M.T.; Rengifo Salgado, E.; Nicoletti, M.; Tomassini, L. New cholinesterase inhibiting bisbenzylisoquinoline alkaloids from Abuta grandifolia. Fitoterapia, 2012, 83(3), 476-480.
[http://dx.doi.org/10.1016/j.fitote.2011.12.015] [PMID: 22230193]
[16]
Tang, H.; Zhao, L-Z.; Zhao, H-T.; Huang, S-L.; Zhong, S-M.; Qin, J-K.; Chen, Z-F.; Huang, Z-S.; Liang, H. Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors. Eur. J. Med. Chem., 2011, 46(10), 4970-4979.
[http://dx.doi.org/10.1016/j.ejmech.2011.08.002] [PMID: 21871694]
[17]
(a) aLi, Y-P.; Ning, F-X.; Yang, M-B.; Li, Y-C.; Nie, M-H.; Ou, T-M.; Tan, J-H.; Huang, S-L.; Li, D.; Gu, L-Q.; Huang, Z.S. Syntheses and characterization of novel oxoisoaporphine derivatives as dual inhibitors for cholinesterases and amyloid beta aggregation. Eur. J. Med. Chem., 2011, 46 (5), 1572-1572.
[http://dx.doi.org/10.1016/j.ejmech.2011.02.005] [PMID: 21367493]
(b) Tang, H.; Zhao, H-T.; Zhong, S-M.; Wang, ZY.; Chen, Z-F.; Liang, H. Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase- induced beta-amyloid aggregation. Bioorg. Med. Chem. Lett., 2012, 22(6), 2257-2261.
[http://dx.doi.org/10.1016/j.bmcl.2012.01.090] [PMID: 22341944]
[18]
Tang, H.; Wei, Y-B.; Zhang, C.; Ning, F-X.; Qiao, W.; Huang, S-L.; Ma, L.; Huang, Z-S.; Gu, L-Q. Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinesterase/butyrylcholinesterase. Eur. J. Med. Chem., 2009, 44(6), 2523-2532.
[http://dx.doi.org/10.1016/j.ejmech.2009.01.021] [PMID: 19243862]
[19]
Prado-Prado, F.; García-Mera, X.; Escobar, M.; Sobarzo-Sánchez, E.; Yañez, M.; Riera-Fernandez, P.; González-Díaz, H.; Riera-Fernandez, P. 2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins. Eur. J. Med. Chem., 2011, 46(12), 5838-5851.
[http://dx.doi.org/10.1016/j.ejmech.2011.09.045] [PMID: 22005185]
[20]
Pecic, S.; McAnuff, M.A.; Harding, W.W. Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations. J. Enzyme Inhib. Med. Chem., 2011, 26(1), 46-55.
[http://dx.doi.org/10.3109/14756361003671078] [PMID: 20583856]
[21]
Jung, H.A.; Min, B-S.; Yokozawa, T.; Lee, J-H.; Kim, Y.S.; Choi, J.S. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol. Pharm. Bull., 2009, 32(8), 1433-1438.
[http://dx.doi.org/10.1248/bpb.32.1433] [PMID: 19652386]
[22]
Lashuel, H.A.; Hartley, D.M.; Balakhaneh, D.; Aggarwal, A.; Teichberg, S.; Callaway, D.J.E. New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer’s disease. J. Biol. Chem., 2002, 277(45), 42881-42890.
[http://dx.doi.org/10.1074/jbc.M206593200] [PMID: 12167652]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 18
Year: 2019
Page: [3253 - 3259]
Pages: 7
DOI: 10.2174/0929867325666180514102933
Price: $58

Article Metrics

PDF: 15
HTML: 2
EPUB: 1
PRC: 1